

Joshua Galuska

BERKELEY RESEARCH GROUP, LLC

Washington, DC | Richmond, VA

Direct: 202.839.3947

jgaluska@thinkbrg.com

SUMMARY

Joshua Galuska is a Director with BRG's Healthcare practice. He specializes in False Claims Act (FCA) investigations and litigation, with a focus on healthcare and life sciences matters. He combines deep healthcare industry knowledge with sophisticated data analytics to develop rigorous, data-driven analyses for clients facing disputes, government investigations, and litigation.

Mr. Galuska leads project teams on engagements involving pharmaceutical manufacturers, medical device companies, pharmacy benefit managers, and health plan clients. His clients are typically facing qui tam matters, government investigations, and civil litigation related to the FCA, anti-kickback statute (AKS), regulatory compliance and reporting requirements, and allegations of off-label marketing and drug pricing and billing fraud.

His work typically involves developing data models employing client internal data, public healthcare datasets, and third-party market data to measure potential liability and exposure, support testifying experts, and inform settlement negotiations. Mr. Galuska has presented investigation analyses to the Civil and Criminal Divisions of the US Department of Justice on behalf of clients and their outside counsel.

Mr. Galuska is a certified fraud examiner (CFE). He combines technical expertise with a detailed understanding of healthcare pricing, the healthcare supply chain, and claims and reimbursement to deliver sophisticated answers to complex questions for clients and their legal counsel.

EDUCATION

BA, Economics

College of William and Mary, 2016

CERTIFICATIONS

Certified Fraud Examiner (CFE)

Association of Certified Fraud Examiners (ACFE)

PRESENT EMPLOYMENT

BERKELEY RESEARCH GROUP, Washington DC, 2017 - Present

Director

RECENT PUBLICATIONS

- (1) “CMS 2026 Final Rule and Program Instructions Codify IRA Part D Provisions in Preparation for First Year of Selected Drugs Under Medicare Drug Price Negotiation Program.” Bulletin, American Health Law Association, May 2025.
- (2) “An Update on Post-Pandemic Financial Relationships Between Manufacturers and Practitioners.” Whitepaper, BRG, October 2024.
- (3) “CMS Releases First Round of Medicare Price Negotiation.” Whitepaper, BRG, August 2024.
- (4) “Have Financial Relationships Between Manufacturers and Practitioners Returned to Pre-Pandemic Levels?” Whitepaper, BRG, June 2024.
- (5) “Inflation Reduction Act Drug-Pricing Provisions: Financial Impact on Manufacturers,” May 2023.
- (6) “Inflation Reduction Act Drug-Pricing Provisions,” February 2023.

RECENT SPEAKING EVENTS

- (1) *“The 2026 MA and Part D Final Rule What’s In and What’s Out”, American Health Law Association Webinar, May 2025*
- (2) *“IRA – Part D Redesign Deep Dive”, BRG Webinar, October 2023*

SELECT PROFESSIONAL EXPERIENCE

Medical Device Manufacturer FCA and AKS Investigation

- Provided privileged consulting and data analytics support to outside counsel for a large manufacturer of medical device capital equipment that was the subject of a DOJ subpoena and civil investigative demand related to alleged anti-kickback violations.
- Assisted with collection and production of data in response to the DOJ’s requests for information on equipment sales, donated and loaned equipment, and all provider remunerations including speaker fees, sponsorships, meals, entertainment, and travel reimbursement.
- Analyzed the company’s transactional sales, accounting, employee expenses, and loaner inventory data to identify responsive transactions to evaluate the DOJ’s theories of liability, understand the scope of the allegations, and develop potential exposure estimates.
- Developed models that were used as the basis for settlement with the government and supported outside counsel on several presentations to the Civil and Criminal divisions of the DOJ.

Pharmaceutical Manufacturer FCA Trade Compliance Investigation

- Provided privileged consulting and analytics support to outside counsel and in-house counsel for a global medical device manufacturer subject to a Department of Justice investigation related to alleged violations of Trade Agreements Act and Buy American Act.

- Developed model to evaluate the country of origin for each U.S. sale and identify products sold to government customers which were manufactured in non-designated countries.
- Drafted short investigation reports and personally presented results to the Civil Division and the Criminal Division of the US Department of Justice in connection with settlement discussions.

Pharmaceutical Manufacturer FCA and AKS Investigation

- Provided discovery assistance, potential exposure analyses, and litigation support to outside counsel for a pharmaceutical manufacturer facing a qui tam action that alleged millions of dollars in reimbursements under Medicare and Medicaid were both the result of a government pricing scheme and induced by kickbacks the manufacturer provided to healthcare providers through free sample/promotional programs.
- Developed model to evaluate the impact of the promotional pricing on best price, ASP, AMP, and consequently on Medicaid unit rebate amount calculations based on AMP to support settlement negotiations.

Pharmacy Benefit Manager Rebate Dispute

- Assisted in the preparation for expert testimony and drafting of an expert report.
- Analyzed millions of pharmacy claim transactions to calculate alleged underpayments and model potential exposure.

Medical Device Manufacturer Compliance Analytics Technical Implementation

- Provided consulting services to a medical device manufacturer compliance function looking to build an in-house custom solution to visualize transactional data from SAP.
- Worked alongside the business and technical teams to develop requirements, identify the necessary data structures, map the relationships in the database, and validate data was not duplicated or missing in the process of migrating the custom reporting solution from SAP ECC to SAP HANA.
- Developed a prototype tool based on a relational database recreated in SQL and worked with the technical team to implement the solution on the live data.

Pharmaceutical Manufacturer Controlled Substance Act Litigation

- Provided litigation support to outside counsel for a pharmaceutical manufacturer facing several complex lawsuits related to violation of the Controlled Substance Act, product liability, false advertising, and public nuisance claims.
- Analyzed millions of rows of internal sales, chargebacks, along with third-party vendor prescription data to evaluate, critique, and provide data-driven analytics to refute plaintiff's theories of liability in each case.

Pharmacy Benefit Manager Breach of Contract Dispute

- Provided potential damages models and analyzed allegations of wrongful termination brought by compounding pharmacies against the PBM.